Comprehensive Study Notes on Bacterial Antibiotic Resistance in Bacteria

Definition and Global Reality of Antibiotic Resistance

Antibiotic resistance occurs when a bacterial strain is capable of growing in the presence of an antibiotic at a concentration significantly higher than the concentration that inhibits the growth of other bacteria of the same species. This phenomenon raises critical clinical questions regarding the efficacy of increasing dosages and the subsequent risk of heightened adverse effects. In the context of public health, the World Health Organization (WHO) highlights a critical situation regarding antibiotic use. Antibiotics account for over $50\%$ of the total volume of drugs used and are the most commonly sold drug group in private pharmacies. Approximately $88 \% \text{ to } 97\%$ of pharmacies sell antibiotics without a prescription. Furthermore, one-third of inpatient prescriptions are deemed inappropriate. Other contributing factors to the crisis include self-diagnosis and self-prescription by patients, improper use of antibiotics due to the insufficient role of pharmacists, and the indiscriminate use of antibiotics in agriculture.

Methods for In Vitro Determination of Antibiotic Resistance

Standardized methods for identifying resistance in a laboratory setting include dilution and diffusion techniques. The dilution method is used to determine the Minimum Inhibitory Concentration (MIC), which is the lowest concentration of an antibiotic that prevents visible bacterial growth. This can be performed via broth dilution or agar dilution. In a typical procedure, isolated colonies of a bacterial strain are obtained and cultured overnight in a rich media broth. Rich broth with an appropriate dilution series of the test antibiotic is then added to test tubes, often with Final densities of $5 \times 10^5\,cfu/ml$. For example, an antibiotic might be tested at concentrations such as $0.5, 2, 4, 8, 16, 32, 64, 128, \text{ and } 256\,mg/L$. If visible growth is stopped at $64\,mg/L$, the MIC is recorded as $64\,mg/L$. Micro-dilution methods follow a similar logic, often using 96-well plates to determine MICs for various drugs like clindamycin, penicillin, or erythromycin.

The Disk Diffusion method (Kirby-Bauer) and the E-Test are also widely utilized. The E-Test uses a strip with a predefined gradient of antibiotic concentrations to determine the MIC directly on an agar plate. Beyond these phenotypic methods, molecular techniques are employed for faster or more specific identification. Molecular biology methods such as PCR assays are used to identify resistance genes, such as $bla$ genes for beta-lactamases. A typical PCR assay for beta-lactamases involves picking a colony, suspending it in $0.1\% \text{ Triton X-100}$, heating it at $100^{\circ}C$ for $10\,min$, and centrifuging at $18,000\,g$ for $1\,min$. The supernatant is then subjected to multiplex PCR with specific temperature cycles (e.g., $95^{\circ}C$ for $5\,min$, followed by 30 cycles of $95^{\circ}C$ for $30\,sec$, $64^{\circ}C$ for $40\,sec$, and $72^{\circ}C$ for $50\,sec$). Additionally, Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) is used to identify resistance by evaluating bacterial spectra and beta-lactam ring hydrolysis.

Classification and Biological Basis of Resistance

Antibiotic resistance is broadly classified into natural (intrinsic) resistance and acquired (thụ nhận) resistance. Intrinsic resistance is an inherent characteristic common to an entire genus or species, typically rooted in the bacterial chromosome. The mechanisms for intrinsic resistance include poor permeability of the cell envelope, the presence of efflux pumps, the lack of a specific target, or a low affinity for the drug target. A classic example is $Mycoplasma\,sp.$, which is naturally resistant to beta-lactam antibiotics because it lacks a peptidoglycan cell wall.

Acquired resistance develops when a previously sensitive bacterial strain becomes resistant through chromosomal mutations or the acquisition of new genetic material. Chromosomal mutation-based resistance can be triggered by antibiotics (such as polypeptides), chemical agents, or ultraviolet radiation. These mutations can also occur through replication errors, with frequencies typically ranging from $10^{-8}$ to $10^{-9}$. In a population of $E.\,coli$ with a genome of $4.2\,Mbps$ ($8.4$ million bases), a mutation frequency of $10^{-9}$ means that every time the bacteria divide, the offspring will have $0.0084$ mutated bases. This implies that approximately $1\%$ of the microbial population will contain at least one mutation per chromosome, leading to natural selection in the presence of antibiotics.

Mechanisms of Horizontal Gene Transfer and Transposons

Acquired resistance often involves the transfer of resistance genes between bacteria via three primary mechanisms: conjugation, transformation, and transduction. Conjugation is the direct contact between two bacterial cells using a sex pilus, where genetic material (often a plasmid) is transferred from a donor (e.g., an $F^+$ cell) to a recipient ($F^-$ cell). Resistance plasmids (R factors) are particularly significant because they can carry multiple resistance genes and a Resistance Transfer Factor (RTF) region. Plasmid-mediated resistance accounts for $80 \% \text{ to } 90\%$ of acquired resistance cases and allows for the rapid spread of multi-drug resistance across different species.

Transposons, or "jumping genes," are small DNA segments that can move between plasmids, from plasmids to chromosomes, or vice versa. These segments are flanked by inverted repeat (IR) sequences and often carry resistance genes. Important transposons include $Tn3, Tn4, Tn5, \text{ and } Tn10$. Migration can occur via non-replicative (conservative) transposition, where the transposon is physically moved, or replicative transposition, where a copy is made and integrated into a new location through a process involving a cointegrate intermediate and resolution. This genetic mobility ensures that resistance genes can be disseminated efficiently throughout a bacterial community.

Fundamental Mechanisms and Targets of Antibiotics

To effectively combat bacteria, an antibiotic must reach its target in a sufficient concentration and inhibit or destroy that target specifically. The primary targets of modern antibiotics include:

1. Peptidoglycan cell wall synthesis: Inhibited by beta-lactams (penicillins, cephalosporins, carbapenems, monobactams) and glycopeptides.

2. Cell membrane integrity: Disrupted by polymyxins (like colistin) which target the lipopolysaccharide (LPS).

3. DNA replication: Targeting DNA gyrase (topoisomerase II), which relaxes supercoiled DNA, and topoisomerase IV, which unlinks replicated strands. Quinolones and fluoroquinolones are the primary agents here.

4. Transcription (RNA synthesis): Inhibited by rifamycins (such as rifampin), which bind to the $\beta$-subunit of DNA-dependent RNA polymerase.

5. Protein synthesis: Targeting the $30S$ subunit (aminoglycosides, tetracyclines) or the $50S$ subunit (macrolides, oxazolidinones like linezolid, chloramphenicol, clindamycin, streptogramins).

6. Folate metabolism: Inhibited by sulfonamides (competing with PABA) and trimethoprim (inhibiting DHF to THF conversion).

Routes of Antibiotic Entry into Bacterial Cells

Antibiotics must bypass outer bacterial layers to reach their targets. Gram-positive bacteria have a thick, relatively permeable peptidoglycan layer that allows molecules up to $30 \text{ to } 57\,kDa$ to pass through. In contrast, Gram-negative bacteria possess an outer membrane (OM) composed of phospholipids and Lipopolysaccharides (LPS). The saturated hydrocarbon chains of LPS are tightly packed, making the OM a formidable barrier. Hydrophilic antibiotics (beta-lactams, aminoglycosides, quinolones) enter Gram-negative cells through porins. There are two types: non-specific porins (allowing substances < 1.5\,kDa) and specific porins (requiring receptor binding). Lipid-soluble antibiotics (rifampicin, macrolides, fusidic acid) often face barriers in Gram-negative bacteria but easily penetrate Gram-positive walls. The penetration of antibiotics depends on the antibiotic's size, charge, and lipophilicity, as well as the number and size of the bacterial porins.

Resistance via Altered Permeability and LPS Modification

Bacteria can reduce antibiotic entry through several structural changes. Some bacteria produce capsules ($Klebsiella\,sp., Haemophilus\,sp., Neisseria\,sp., S. pneumoniae$) or extracellular polysaccharides like alginate to form biofilms ($P.\,aeruginosa$), which severely slow drug diffusion. Modification of the LPS structure in the outer membrane can also regulate permeability. Bacteria can lengthen the polysaccharide core or add positively charged groups to Lipid A (such as aminoarabinose, glycine, or phosphoethanolamine) to decrease the binding of cationic antibiotics like polymyxins. For instance, $P.\,aeruginosa$ and $Salmonella\,typhimurium$ attach aminoarabinose to Lipid A, while $Vibrio\,cholerae$ attaches glycine and diglycine.

Furthermore, bacteria can alter porin expression. In $E.\,coli$, the non-specific channels $OmpC$ and $OmpF$ can be down-regulated or replaced by more specific channels to limit entry. In $P.\,aeruginosa$, the loss or mutation of the $OprD$ (Porin D2) channel specifically confers resistance to carbapenems without affecting other beta-lactams. In terms of cytoplasmic membrane permeability, aminoglycosides require energy and oxygen for transport. Consequently, anaerobic bacteria or those with weak electron transport systems (like $Streptococcus$) exhibit intrinsic resistance because they cannot generate the required ATP for drug uptake.

Resistance via Efflux Pump Systems

Efflux pumps are active transport systems that expel antibiotics from the cell, lowering the internal concentration below effective levels. There are five major families of multidrug efflux pumps:

1. ATP-binding cassette (ABC) superfamily: Uses ATP hydrolysis (e.g., $LmrA$).

2. Major facilitator superfamily (MFS): Uses the proton motive force (e.g., $NorA, QacA, Mef(A)$).

3. Multidrug and toxic compound extrusion (MATE) family: Uses sodium or proton gradients (e.g., $NorM, CdeA$).

4. Small multidrug resistance (SMR) family: e.g., $QacC, Smr$.

5. Resistance nodulation division (RND) family: Particularly important in Gram-negative bacteria where they span both membranes (e.g., $AcrAB-TolC$ in $E.\,coli$ and $MexAB-OprM$ in $P.\,aeruginosa$).

In $P.\,aeruginosa$, the $MexAB-OprM$ system has a broad substrate profile including beta-lactams, fluoroquinolones, tetracyclines, and macrolides. In $Acinetobacter\,baumannii$, the $AdeABC$ (RND family) pump expels aminoglycosides, fluoroquinolones, tetracyclines, and tigecycline. Similarly, $S.\,aureus$ utilizes $NorA$, $NorB$, and $MdeA$ to resist norfloxacin and ciprofloxacin.

Resistance via Modification of the Target Site

Mutation-induced structural changes in the target site can drastically reduce antibiotic affinity. One major example is the alteration of Penicillin Binding Proteins (PBPs). In Methicillin-resistant $S.\,aureus$ (MRSA), the acquisition of the $mecA$ gene (carried on the Staphylococcal Cassette Chromosome mec or $SCCmec$) leads to the production of $PBP2A$ (also known as $PBP2'$). $PBP2A$ has a very low affinity for all beta-lactam antibiotics. Similarly, mutations in $PBP2X$ or $PBP2B$ in $Streptococci$ confer penicillin resistance.

Another example is the modification of the peptidoglycan peptide chain. Vancomycin resistance in $Enterococci$ is achieved by changing the terminal $D-Ala-D-Ala$ sequence to $D-Ala-D-Lactate$, a change mediated by the $vanA, vanB, \text{ or } vanC$ gene clusters. The transfer of the $vanA$ gene cluster via the transposon $Tn1546$ from $Enterococcus\,sp.$ to MRSA results in Vancomycin-resistant $S.\,aureus$ (VRSA). Ribosomal resistance occurs when genes like $erm$ encode methyltransferases that methylate the $23S\,rRNA$ of the $50S$ subunit, causing resistance to macrolides, lincosamides, and streptogramin B. In quinolone resistance, mutations in the $GyrA$ subunit of DNA gyrase or the $ParC$ subunit of topoisomerase IV reduce drug binding.

Resistance via Enzymatic Inactivation and Destruction

Bacteria produce enzymes that chemically modify or destroy antibiotics. Aminoglycosides are frequently inactivated by modifying enzymes:

• Acetyltransferase (AAC): Adds an acetyl group.

• Phosphotransferase (APH): Adds a phosphate group.

• Nucleotidyltransferase (ANT): Adds an adenyl group.

The most prominent destructive enzymes are $\beta$-lactamases, which hydrolyze the beta-lactam ring. These are classified by the Bush-Jacoby system into four functional groups:

• Group 1: Cephalosporinases not inhibited by clavulanic acid.

• Group 2: Broad-spectrum penicillinases/cephalosporinases inhibited by clavulanic acid (includes $2a, 2b, 2be$ [ESBL], $2c, 2d, 2e, 2f$).

• Group 3: Metallo-beta-lactamases (MBLs) that require Zinc ($Zn^{2+}$) and can hydrolyze carbapenems.

• Group 4: Penicillinases not inhibited by clavulanic acid (now rare).

Molecular classification (Ambler) divides them into Class A, C, D (serine-based) and Class B (Zinc-based). Extended Spectrum Beta Lactamases (ESBLs) are a critical sub-group (mostly Class A on plasmids) that destroy oxyimino-cephalosporins (ceftazidime, ceftriaxone) and monobactams. Common types include $TEM-1, SHV-1, CTX-M$, and $OXA$ (Class D).

Multidrug Resistance and the ESKAPE Pathogens

Multidrug resistance (MDR) is prevalent in hospital-acquired infections and can result from a single mechanism with broad specificity (like an RND efflux pump) or multiple independent mechanisms (e.g., combining $bla$ genes, PBP mutations, and ribosome mutations). $Pseudomonas\,aeruginosa$ is a prime example of an MDR pathogen, utilizing $MexAB-OprM$, porin loss, and beta-lactamase production simultaneously. The acronym "ESKAPE" denotes the most problematic resistant pathogens in clinical settings:

• E: $Enterococcus\,faecium$

• S: $Staphylococcus\,aureus$

• K: $Klebsiella\,pneumoniae$

• A: $Acinetobacter\,baumannii$

• P: $Pseudomonas\,aeruginosa$

• E: $Enterobacter\,species$

These organisms utilize a vast array of mechanisms—from target modification and drug degradation to cell wall synthesis inhibition bypass—to escape the effects of nearly all current therapeutic options.